Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (4982)	11/11/1997 2:30:00 PM
From: John Metcalf	Read Replies (1) \| Respond to of 9262

{ SCLN } Sciclone is testing Zadaxin against Hepatitis B and C. They didn't command much respect when their trials were being run in Phillipines and China, countries with less rigorous approval standards than the US. However, the have now published a US study conducted in an army hospital. Zadaxin is a compound that has been around awhile. Some believe that this is just a re-packaging of a failed, but licensable, drug. Because of the prevalence of hepatitis B and C, particularly in Asia, the company gets attention from time to time. There are companies with stronger approaches, particularly Gilead. Also, a number of companies solved the HCV protease 3-D structure and are working in very targetted ways on inhibition of HCV. These include AGPH and VRTX, amongst others.